LONDON, March 3, 2026 (ITIA Media Release)

The International Tennis Integrity Agency (ITIA) today confirms that Romeo Arcuschin, an 18-year-old tennis player from Argentina, has been provisionally suspended under the Tennis Anti-Doping Programme (TADP).

The ITIA sent the player a pre-charge notice of an Anti-Doping Rule Violation on 16 February 2026 under Article 2.1 of the TADP (presence of a Prohibited Substance in a Player’s Sample) and/or Article 2.2 (Use of a Prohibited Substance without a valid Therapeutic Use Exemption (TUE)).

Arcuschin, who reached a career-high world singles ranking of 1802 in November 2025, provided an in-competition sample while competing in an ITF World Tennis Tour M15 event in Lima, Peru, on 15 December 2025.

The sample was split into A and B samples and the subsequent analysis found that the A sample contained a metabolite of stanozolol. The substance is prohibited under the TADP in the category of Anabolic Agents (Section S1.1) of the 2025 Prohibited List. The B sample was analysed on 23 February 2026 and confirmed the findings of the A sample.

As stanozolol is a non-Specified substance, a mandatory provisional suspension is required. In Arcuschin’s case this has been in effect from 16 February 2026.

Players have the right to appeal the imposition of their provisional suspension before an independent tribunal chair. To date, Arcuschin has not appealed.

While provisionally suspended, Arcuschin is prohibited from playing in, coaching at, or attending any tennis event authorised or sanctioned by the members of the ITIA (ATP, ITF, WTA, Tennis Australia, Fédération Française de Tennis, Wimbledon and USTA) or any national association.